Form 4: Inhibrx Biosciences Director Jon Faiz Kayyem Increases Stake in Company

Director Jon Faiz Kayyem reports purchasing additional shares of Inhibrx Biosciences, Inc. through a family trust.

Summary

• On June 5, 2024, Jon Faiz Kayyem, a director of Inhibrx Biosciences, Inc., acquired additional shares of the company's common stock through The Jon F. Kayyem and Paige Gates-Kayyem Family Trust.
• The trust purchased 49,284 shares at a weighted average price of $17.23, in prices ranging from $16.81 to $17.805.
• Following this transaction, the trust held 1,142,145 shares.
• The trust also purchased 8,265 shares at a weighted average price of $17.89, in prices ranging from $17.81 to $18.10.
• Following this transaction, the trust held 1,150,410 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director purchasing shares, which can be seen as a positive signal, but it's not overwhelmingly positive.

Positives

• The director's purchase of additional shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be a signal to the market.

Key Dates